Indegene (INDGN) Fundamentals 2026 — P/E 29.5x, Revenue Analysis | SniperIQ
Indegene (INDGN) is a India-listed Healthcare company in Medical - Healthcare Information Services with a market capitalization of ₹11,915 Crore, trading at ₹493.75 on the BSE. This SniperIQ fundamentals page covers Indegene's valuation (P/E 29.5x, P/B 3.8x), profitability (net margin 11.4%), revenue (₹3,511 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Indegene's market cap?
Indegene (INDGN) has a market capitalization of approximately ₹11,915 Crore, trading at ₹493.75 on the BSE. Market cap moves with the live share price.
What is Indegene's P/E ratio?
Indegene's trailing twelve-month P/E ratio is 29.5x, with a price-to-book (P/B) of 3.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Indegene?
Indegene runs a net profit margin of 11.4%, a gross margin of 55.3%, and an operating margin of 14.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Indegene generate?
Indegene reported revenue of ₹3,511 Crore for fiscal year 2026, with net income of ₹401 Crore and earnings per share (EPS) of 16.72. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Indegene pay a dividend?
Indegene does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Indegene financially healthy?
Indegene carries a debt-to-equity ratio of 0.05x and a current ratio of 2.41x, with a market beta of 0.73. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Indegene a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Indegene (INDGN) the key facts are: market cap ₹11,915 Crore, P/E 29.5x, revenue ₹3,511 Crore, 52-week range 414.9-596.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Indegene's full fundamentals live
Get Indegene's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.